Reserved

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
星期一, 四月 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors

Retrieved on: 
星期五, 二月 9, 2024
Health, Medical Devices, Genetics, Research, Science, Pharmaceutical, Biotechnology, Stifel, Sofinnova, Ototoxicity, Quality of life, GJB2, Huber loss, Euronext Growth, Code, Chair, SVB Securities, EUR, Pasteur Institute, Clinical trial, Patient, Reserved, Person, Commercial code, Audiology

The settlement-delivery of the Reserved Offering is expected to take place around February 13, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around February 13, 2024, subject to customary conditions.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “We are delighted to announce today’s successful capital raise of EUR 50.5 million.
  • This strengthened shareholder base reinforces Sensorion’s ambition to advance its pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Biophytis launches a round of fundraising for approximately 2 million euros

Retrieved on: 
星期三, 五月 10, 2023
EUA, 20F, Euronext Growth, CET, Therapy, Code, Marketing, Bookrunner, Reserved, COVID-19, Ageing, Emergency Use Authorization, China Investment Securities, Overalls, Mass meeting, Attention, Risk, Annual general meeting, EMA, European Medicines Agency, EUR, Criticism of the Food and Drug Administration, Euronext, Patient, ISIN, Combined, Marketing Authorisation Application, FDA, MAA, Death, Marketing authorisation, Food, Respiratory failure, Cryptocurrency, Pharmaceutical industry, Auction, Security (finance), Risk management

The price of the shares allocated in connection with the PrimaryBid Offer will be identical to that determined for the Reserved Offer.

Key Points: 
  • The price of the shares allocated in connection with the PrimaryBid Offer will be identical to that determined for the Reserved Offer.
  • For the PrimaryBid Offer, investors will be able to subscribe exclusively through the PrimaryBid partners indicated on the PrimaryBid site (www.PrimaryBid.fr).
  • The risk factors presented in said documents are identical on the date of this press release.
  • Such events could have a significant adverse impact on the market price of Biophytis shares.